Comparison of Anesthetic Efficacy of Bilateral and Unillateral Application of Kovacaine Mist in Healthy Volunteers

NCT ID: NCT02457806

Last Updated: 2016-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the efficacy of Kovacaine Mist administered bilaterally to that of Kovacaine Mist administered unilaterally with respect to global profound pulpal anesthesia in target teeth numbers 4-13.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Qualified and consenting healthy subjects will be randomly assigned in a double-blind manner to sequences of four randomly ordered study periods with inter-treatment "washout" periods of 3 to 14 days. The four study regimens, which will be applied in random order will be:

* Regimen1. Three sprays of Kovacaine Mist in each nostril (bilateral dosing);
* Regimen 2. Three sprays of Kovacaine Mist in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing);
* Regimen 3. Three sprays of Kovacaine Mist in the left nostril and three sprays of placebo in the right nostril (left-sided unilateral dosing);
* Regimen 4. Three sprays of placebo in each nostril (placebo dosing).

During each testing period, eight representative maxillary teeth (#s 3, 4, 6, 8, 9, 11, 13 and 14) will be assessed for anesthesia using standard EPT testing. EPT testing will be conducted on the eight representative teeth at the following time points (minutes relative to the first spray of study drug): T-5, T3, T7, T11, T16, T21, T26T31, T41, T51, T61, T76, T91, T121, T151, and T181. If EPT testing of a target tooth is not possible (e.g., missing or does not meet inclusion criterion #2) tooth substitution is permissible. For molar teeth, #2 may replace #3 and #15 may replace #14. For premolar teeth, #5 may replace #4 and #12 may replace #13. The same replacements will be made for all testing sessions, and the actual teeth tested will be documented in the CRF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dental Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Kovacaine Mist

3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart

Group Type EXPERIMENTAL

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Intervention Type DRUG

Active Spray with deliverable volume of 0.1 mL

Kovacaine Mist and Placebo

3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart

Group Type ACTIVE_COMPARATOR

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Intervention Type DRUG

Active Spray with deliverable volume of 0.1 mL

Placebo spray

Intervention Type DRUG

Aqueous solution to deliver 0.1 mL per unit

Placebo and Kovacaine Mist

3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart

Group Type ACTIVE_COMPARATOR

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Intervention Type DRUG

Active Spray with deliverable volume of 0.1 mL

Placebo spray

Intervention Type DRUG

Aqueous solution to deliver 0.1 mL per unit

Placebo spray

3 sprays of placebo in each nostril administered 4 minutes apart

Group Type PLACEBO_COMPARATOR

Placebo spray

Intervention Type DRUG

Aqueous solution to deliver 0.1 mL per unit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Active Spray with deliverable volume of 0.1 mL

Intervention Type DRUG

Placebo spray

Aqueous solution to deliver 0.1 mL per unit

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Kovacaine Mist Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 18 years of age or older.
* Eight representative maxillary teeth \[(3 (or 2), 4 (or 5), 6, 8, 9, 11, 13 (or 12), and 14 (or15)\] free of observable decay (or other pathology), crowns or veneers, all of which have EPT values of 10-50 at screening.
* Normal lip, nose, eyelid, palate, and cheek sensation.
* Patency of both left and right nasal airways.
* Ability to understand and willingness to sign the study informed consent form, communicate with study investigators, and understand and comply with the requirements of the study protocol.

Exclusion Criteria

* Poorly controlled hypertension (blood pressure greater than 150/90 mmHg) or history of coronary heart disease.
* Diabetes mellitus.
* Any active thyroid disease other than S/P thyroidectomy on thyroid hormone replacement with TSH values in the normal range.
* History or presence of narrow-angle glaucoma.
* Prostatic enlargement.
* History of sinus/nasal surgery that, in the opinion of the investigator, could confound study results.
* History of frequent nose bleeds.
* Receipt of dental care requiring a local anesthetic within the last 24 hours.
* History of allergy to or intolerance of tetracaine, benzyl alcohol, benzocaine, other ester local anesthetics, succinylcholine, or para-aminobenzoic acid (as found in PABA-containing sunscreens).
* History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or sulfite antioxidants.
* History of drug abuse.
* Use of a monoamine oxidase inhibitor within the 3 weeks immediately prior to anticipated study participation.
* Nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females will be required to undergo pregnancy testing to rule out pregnancy)
* Use of any investigational drug and/or participation in a clinical research trial within 30 days of the first study dosing day.
* Requirement for uninterrupted use of any medication with actions that might, in the opinion of the involved investigator, confound interpretation of study results.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Renatus, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrick R Brain, DDS

Role: PRINCIPAL_INVESTIGATOR

Jean Brown Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jean Brown Research

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SR 2-04

Identifier Type: -

Identifier Source: org_study_id